109 related articles for article (PubMed ID: 26940276)
1. Therapy Effect: Impact on Bone Marrow Morphology.
Li KD; Salama ME
Surg Pathol Clin; 2016 Mar; 9(1):177-87. PubMed ID: 26940276
[TBL] [Abstract][Full Text] [Related]
2. MR imaging of therapy-induced changes of bone marrow.
Daldrup-Link HE; Henning T; Link TM
Eur Radiol; 2007 Mar; 17(3):743-61. PubMed ID: 17021706
[TBL] [Abstract][Full Text] [Related]
3. An unexpected association of hematologic malignancies.
Athanase N; Frébet E
Blood; 2018 Oct; 132(14):1545. PubMed ID: 30287471
[No Abstract] [Full Text] [Related]
4. Targeting the bone marrow microenvironment in hematologic malignancies.
Dalton WS; Hazlehurst L; Shain K; Landowski T; Alsina M
Semin Hematol; 2004 Apr; 41(2 Suppl 4):1-5. PubMed ID: 15190509
[TBL] [Abstract][Full Text] [Related]
5. [Role of thalidomide in the treatment of multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis of bone marrow disorders: is MRT sufficient?].
Kramer J
Radiologe; 2007 Aug; 47(8):660-2. PubMed ID: 17721793
[No Abstract] [Full Text] [Related]
7. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
8. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies.
Rajkumar SV; Mesa RA; Tefferi A
J Hematother Stem Cell Res; 2002 Feb; 11(1):33-47. PubMed ID: 11847002
[TBL] [Abstract][Full Text] [Related]
9. Estimation of bone marrow cellularity using digital image nucleated cell counts in patients receiving chemotherapy.
Kim Y; Kim M; Kim Y; Han JH; Han K
Int J Lab Hematol; 2014 Oct; 36(5):548-54. PubMed ID: 24612511
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Hayashi Y
Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
[TBL] [Abstract][Full Text] [Related]
11. MRI of bone marrow abnormalities in hematological malignancies.
Silva JR; Hayashi D; Yonenaga T; Fukuda K; Genant HK; Lin C; Rahmouni A; Guermazi A
Diagn Interv Radiol; 2013; 19(5):393-9. PubMed ID: 23748035
[TBL] [Abstract][Full Text] [Related]
12. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
13. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
14. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
Tallman MS
Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
[TBL] [Abstract][Full Text] [Related]
15. Severe bone marrow necrosis without suggestive features.
Ozkan A; Ozkalemkas F; Ali R; Ozkocaman V; Ozcelik T
Am J Hematol; 2006 May; 81(5):386-7. PubMed ID: 16628718
[No Abstract] [Full Text] [Related]
16. [Autophagy in hematologic malignancies].
Adachi S
Rinsho Ketsueki; 2009 Oct; 50(10):1531-8. PubMed ID: 19915363
[No Abstract] [Full Text] [Related]
17. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.
Ribatti D; Vacca A
Leukemia; 2005 Sep; 19(9):1525-31. PubMed ID: 15973447
[TBL] [Abstract][Full Text] [Related]
18. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
19. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
20. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
Hasserjian RP; Boecklin F; Parker S; Chase A; Dhar S; Zaiac M; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM
Am J Clin Pathol; 2002 Mar; 117(3):360-7. PubMed ID: 11888075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
